Table 2.
Comparison of patients and tumor characteristics by LR-3/4 vs LR-5.
| Variable | LR-3/4 N = 53 |
LR-5 N = 133 |
p-Value 1 |
|---|---|---|---|
| Age, years (median [IQR]) | 65.15 [58.69; 73.39] | 66.81 [57.72; 73.69] | 0.941 |
| Sex = Female (%) | 10 (18.9) | 26 (19.5) | 1.000 |
| Performance Status = 1 (%) | 7 (13.2) | 15 (11.3) | 0.907 |
| Child Pugh class B (%) | 7 (14.9) | 15 (12.4) | 0.86 |
| MELD score, points (median [IQR]) | 8.00 [7.00; 10.00] | 8.00 [7.00; 10.00] | 0.357 |
| ALBI score, points (median [IQR]) | −2.44 [−2.87; −2.09] | −2.51 [−2.77; −2.27] | 0.714 |
| ALBI grade (%) 2 | - | - | 0.693 |
| ALBI grade 1 (%) | 21 (39.6) | 55 (41.7) | - |
| ALBI grade 2 (%) | 29 (54.7) | 73 (55.3) | - |
| ALBI grade 3 (%) | 3 (5.7) | 4 (3.0) | - |
| log10αFP, ng/mL (median [IQR]) | 0.95 [0.63; 1.35] | 1.30 [0.75; 2.09] | 0.028 |
| Multinodular tumor (%) | 10 (18.9) | 39 (29.3) | 0.202 |
| Maximum tumor size, mm (median [IQR]) | 30.00 [23.00; 50.00] | 35.00 [24.00; 55.00] | 0.428 |
| BCLC (%) 3 | - | - | 0.322 |
| BCLC = 0 (%) | 11 (20.8) | 17 (12.8) | - |
| BCLC = A (%) | 26 (49.1) | 64 (48.1) | - |
| BCLC = B (%) | 12 (22.6) | 45 (33.8) | - |
| BCLC = C (%) | 4 (7.5) | 7 (5.3) | - |
| Tumor grading (%) 4 | - | - | 0.178 |
| Tumor grading = 1 (%) | 8 (15.4) | 9 (6.9) | - |
| Tumor grading = 2 (%) | 24 (46.2) | 72 (55.0) | - |
| Tumor grading = 3 (%) | 20 (38.5) | 50 (38.2) | - |
| Microvascular invasion (%) | 12 (22.6) | 55 (41.7) | 0.024 |
| Satellitosis (%) | 5 (9.4) | 34 (25.8) | 0.024 |
| Capsule infiltration (%) | 6 (11.3) | 37 (28.0) | 0.025 |
| R0 resection (%) | 47 (94.0) | 106 (84.1) | 0.132 |
| Liver transplant after resection (%) | 7 (13.2) | 16 (12.2) | 1.000 |
1 Chi-square or Mann–Whitney test p-value; 2 p-value is referred to ALBI grade 1,2,3 in the two groups; 3 p-value is referred to BCLC 0, A, B, C in the two groups; 4 p-value is referred to tumor grading 1, 2, 3 in the two groups. Abbreviations: MELD, Model for End Stage Liver Disease; ALBI, Albumin-Bilirubin; αFP, alpha-fetoprotein; BCLC, Barcelona Clinic for Liver Cancer.